Post-Chemotherapeutic Administration of Interleukin-12 Retards Tumor Growth and Enhances Immune Cell Function: Combination Therapy Using Paclitaxel and IL-12
- 1 January 2006
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 24 (4) , 351-359
Abstract
The antineoplastic agent paclitaxel (TAXOL) is a potent inhibitor of tumor cell division that also suppresses lymphocyte proliferative responses. Because chemotherapy-induced immunosuppression may limit the patient's antitumor responses, we investigated the possibility that the T cell stimulatory cytokine interleukin-12 (IL-12) could be used to reverse paclitaxel-mediated lymphocyte suppression. Recognizing that IL-12 treatment following paclitaxel exposure promotes T cell responses in vitro, we evaluated the antitumor efficacy of IL-12 administration concurrent and subsequent to paclitaxel treatment. Simultaneous administration of IL-12 and paclitaxel failed to limit tumor outgrowth or extend survival beyond chemotherapy alone, although IL-12 did not manifest negative effects. In contrast, post-chemotherapeutic IL-12 significantly delayed tumor outgrowth and extended survival in tumor-burdened BALB/c mice. Correlative enhancements in ex vivo immune cell effector function were also observed following paclitaxel and temporally delayed IL-12 therapy. Collectively, these data demonstrate an immunotherapeutic efficacy of IL-12 that augments the chemotherapeutic activities of paclitaxel when delivered in the appropriate temporal sequence.Keywords
This publication has 30 references indexed in Scilit:
- Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary TumorClinical Cancer Research, 2005
- Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatmentJournal of Controlled Release, 2005
- Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer modelMolecular Therapy, 2004
- Potential Prophylactic Measures Against Postoperative Immunosuppression: Could They Reduce Recurrence Rates in Oncological Patients?Annals of Surgical Oncology, 2003
- Antitumor Effects on Mouse Melanoma Elicited by Local Secretion of Interleukin-12 and Their Enhancement by Treatment with Interleukin-18Cancer Investigation, 2000
- Interleukin-12 Overcomes Paclitaxel-Mediated Suppression of T-Cell ProliferationImmunopharmacology and Immunotoxicology, 1998
- Potential clinical applications of interleukin-12Current Opinion in Hematology, 1996
- Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycleInternational Journal of Cancer, 1994
- Cytotoxicity of taxol in vitro against human and rat malignant brain tumorsCancer Chemotherapy and Pharmacology, 1994
- Microtubules and lymphocyte responses: Effect of colchicine and taxol on mitogen‐induced human lymphocyte activation and proliferationJournal of Cellular Physiology, 1983